DB:NGQ1

Stock Analysis Report

Executive Summary

Medicure Inc., a pharmaceutical company, engages in the development and commercialization of therapies for the cardiovascular market in the United States.


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Medicure's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NGQ1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.9%

NGQ1

3.3%

DE Biotechs

2.2%

DE Market


1 Year Return

-74.3%

NGQ1

-11.2%

DE Biotechs

-17.2%

DE Market

Return vs Industry: NGQ1 underperformed the German Biotechs industry which returned -8.1% over the past year.

Return vs Market: NGQ1 underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

NGQ1IndustryMarket
7 Day1.9%3.3%2.2%
30 Day-46.2%-6.5%-15.7%
90 Day-64.3%-23.1%-24.0%
1 Year-74.3%-74.3%-11.0%-11.2%-14.9%-17.2%
3 Year-84.2%-84.2%14.9%13.6%-16.4%-23.3%
5 Year-29.6%-29.6%-8.0%-10.3%-16.5%-27.8%

Price Volatility Vs. Market

How volatile is Medicure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medicure undervalued compared to its fair value and its price relative to the market?

0.35x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NGQ1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NGQ1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NGQ1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: NGQ1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NGQ1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NGQ1 is good value based on its PB Ratio (0.3x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Medicure forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

55.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NGQ1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: NGQ1 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NGQ1's is expected to become profitable in the next 3 years.

Revenue vs Market: NGQ1's revenue (20.2% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: NGQ1's revenue (20.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NGQ1's Return on Equity is forecast to be low in 3 years time (13%).


Next Steps

Past Performance

How has Medicure performed over the past 5 years?

6.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NGQ1 is currently unprofitable.

Growing Profit Margin: NGQ1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NGQ1 is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.

Accelerating Growth: Unable to compare NGQ1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NGQ1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: NGQ1 has a negative Return on Equity (-3.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is Medicure's financial position?


Financial Position Analysis

Short Term Liabilities: NGQ1's short term assets (CA$56.5M) exceed its short term liabilities (CA$13.5M).

Long Term Liabilities: NGQ1's short term assets (CA$56.5M) exceed its long term liabilities (CA$4.6M).


Debt to Equity History and Analysis

Debt Level: NGQ1 is debt free.

Reducing Debt: NGQ1 currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: NGQ1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: NGQ1's debt is covered by short term assets (assets are 1.0180837317634E+18x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NGQ1 has been profitable on average in the past, therefore cash runway is not a concern.

Forecast Cash Runway: NGQ1 has been profitable on average in the past, therefore cash runway is not a concern.


Next Steps

Dividend

What is Medicure's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NGQ1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NGQ1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NGQ1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NGQ1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NGQ1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

16.2yrs

Average board tenure


CEO

Albert Friesen (72yo)

no data

Tenure

CA$315,000

Compensation

Dr. Albert David Friesen, Ph.D. serves as Chief Executive Officer and Corporate Secretary and Director at Buffalo Capital Inc. Dr. Friesen serves as Chief Executive Officer at Canam Bioresearch Inc. Dr. Fr ...


CEO Compensation Analysis

Compensation vs Market: Albert's total compensation ($USD222.78K) is below average for companies of similar size in the German market ($USD431.45K).

Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Albert Friesen
Founderno dataCA$315.00k20.44% CA$2.3m
Arnold Naimark
Independent Director20yrsCA$16.00k0.33% CA$37.2k
Gerald McDole
Independent Director16.17yrsCA$11.00k0.45% CA$51.1k
Jeffrey Weitz
Member of Scientific Advisory Boardno datano datano data
Pierre Theroux
Member of Scientific Advisory Boardno datano datano data
Morris Karmazyn
Member of Scientific Advisory Boardno datano datano data
Stephen Hanessian
Member of Scientific Advisory Boardno datano datano data
Paul Armstrong
Chairman of Scientific Advisory Boardno datano datano data
Trevor Hassell
Member of Scientific Advisory Boardno datano data0.020% CA$2.3k
Brent Fawkes
Independent Director7.17yrsCA$16.00k0.11% CA$13.1k

16.2yrs

Average Tenure

75.5yo

Average Age

Experienced Board: NGQ1's board of directors are seasoned and experienced ( 16.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medicure Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medicure Inc.
  • Ticker: NGQ1
  • Exchange: DB
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$17.827m
  • Listing Market Cap: CA$11.428m
  • Shares outstanding: 10.80m
  • Website: https://www.medicure.com

Location

  • Medicure Inc.
  • 2-1250 Waverley Street
  • Winnipeg
  • Manitoba
  • R3T 6C6
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MPHTSXV (TSX Venture Exchange)YesCommon SharesCACADNov 1999
MCUJ.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 1999
NGQ1DB (Deutsche Boerse AG)YesCommon SharesDEEURNov 1999

Biography

Medicure Inc., a pharmaceutical company, engages in the development and commercialization of therapies for the cardiovascular market in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia; Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure; and ReDS, a non-invasive medical device that provides measurement of lung fluid for the management of congestive heart failure. The company was founded in 1997 and is headquartered in Winnipeg, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 21:05
End of Day Share Price2020/03/31 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.